Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders [3]

Blood

Volumn 107, Issue 11, 2006, Pages 4572-4573

  Pardanani, Animesh ^a   Lasho, Terra ^b   McClure, Rebecca ^b   Lacy, Martha ^b   Tefferi, Ayalew ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2;

ALLELE; CHROMOSOME 9P; GENE MUTATION; HEMATOPOIESIS; HETEROZYGOSITY; HUMAN; LETTER; LINKAGE ANALYSIS; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIBLING;

EID: 33744502084     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-12-4988     Document Type: Letter

References (7)

1. Tefferi A, Gilliland DG. JAK2 in myeloproliferative disorders is not just another kinase. Cell Cycle. 2005;4:1053-1056.
2. Perez-Encinas M, Bello JL, Perez-Crespo S, De Miguel R, Tome S. Familial myeloproliferative syndrome. Am J Hematol. 1994;46:225-229.
3. Gilbert HS. Familial myeloproliferative disease. Baillieres Clin Haematol. 1998;11:849-858.
4. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood. 2003;102:3793-3796.
5. Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol. 2005;130:800-801.
6. McClure R, Mai M, Lasho T. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders [letter]. Leukemia. 2006;20:168-171.
7. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945-1953.